Flightpath Biosciences Begins Human Clinical Testing of the World’s First Narrow-Spectrum Antibiotic Targeting Lyme Disease
Flightpath Biosciences Inc., a clinical-stage life sciences company developing therapeutics to treat infectious diseases, announced today that the first healthy volunteer participants have been dosed...
Flightpath Biosciences and the Forsyth Institute Enter Into Co-Development Agreement Targeting Oral Disease
Flightpath Biosciences, Inc. announced today that it has signed a landmark development agreement with the Forsyth Institute, a globally recognized leader in the fields of...